Merck Vioxx Pain Subsides
An Atlantic City, N.J. state court jury verdict clears Merck of allegations the drug maker failed to properly warn patients of risks associated with the use of Vioxx (rofecoxib). "We presented a case that was solidly based on scientific evidence," Merck said. The case, Humeston v. Merck, is the second Vioxx case to reach trial; an Angleton, Texas jury found Merck liable for the death of Robert Ernst in August, awarding his widow $253.5 mil. in damages (1"The Pink Sheet" Aug. 29, 2005, p. 3)...
You may also be interested in...
Merck may opt to settle select Vioxx liability lawsuits in cases where the evidence is clearly in favor of the plaintiff in the wake of the Texas jury verdict against the drug maker
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.